PE20090107A1 - ANTIBODIES BINDING TO THE ANTIGEN IGF-1R - Google Patents
ANTIBODIES BINDING TO THE ANTIGEN IGF-1RInfo
- Publication number
- PE20090107A1 PE20090107A1 PE2008000303A PE2008000303A PE20090107A1 PE 20090107 A1 PE20090107 A1 PE 20090107A1 PE 2008000303 A PE2008000303 A PE 2008000303A PE 2008000303 A PE2008000303 A PE 2008000303A PE 20090107 A1 PE20090107 A1 PE 20090107A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antibody
- fab
- breast
- fragment
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 2
- 210000000481 breast Anatomy 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
REFERIDA A UN ANTICUERPO, HUMANIZADO O QUIMERICO, O FRAGMENTO DE UNION AL ANTIGENO IGF-1R (RECEPTOR DEL FACTOR DE CRECIMIENTO SIMILAR A INSULINA HUMANO) QUE COMPRENDE LA CDR H3 DE LA SEC ID Nº1 O UNA VARIANTE DE LA MISMA CON UNA O DOS SUSTITUCIONES DE AMINOACIDOS EN LA CDRH3 Y QUE COMPRENDE ADEMAS UNA O MAS DE LAS SECUENCIAS CDRH2: SEC ID Nº2 O CDRH1: SEC ID Nº3, CDRL1: SEC ID Nº4, CDRL2: SEC ID Nº7 Y CDRL3: SEC ID Nº6, DONDE EL ANTICUERPO ES UN ANTICUERPO IgG1 Y EL FRAGMENTO ES UN Fab, Fab', F(ab')2, Fv, DIACUERPO, TRIACUERPO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA CELULA HUESPED TRANSFORMADA, TRANSFECTADA O TRANSDUCIDA. DICHO ANTICUERPO TIENE FUNCIONES EFECTORAS O DE ACTIVACION DE COMPLEMENTO Y/O ADCC (CITOTOXICIDAD CELULAR DEPENDIENTE DEL ANTICUERPO) REDUCIDA Y SON UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, PSORIASIS, CANCERES TALES COMO CANCER DE MAMA, PROSTATA, PULMON, ENTRE OTROSREFERRING TO AN ANTIBODY, HUMANIZED OR CHIMERICAL, OR FRAGMENT OF BINDING TO THE ANTIGEN IGF-1R (RECEPTOR OF THE GROWTH FACTOR SIMILAR TO HUMAN INSULIN) THAT INCLUDES THE CDR H3 OF THE SEQ ID Nº1 OR A VARIANT OF THE SAME WITH ONE OR TWO SUBSTITUTES OF AMINO ACIDS IN CDRH3 AND THAT ALSO INCLUDES ONE OR MORE OF THE CDRH2 SEQUENCES: SEQ ID No. 2 OR CDRH1: SEQ ID No. 3, CDRL1: SEQ ID No. 4, CDRL2: SEQ ID No. 7 AND CDRL3: SEQ ID No. 6, WHERE THE ANTIBODY IS A IgG1 ANTIBODY AND THE FRAGMENT IS A Fab, Fab ', F (ab') 2, Fv, DIACBODY, TRIANBODY, AMONG OTHERS. IT IS ALSO REFERRED TO A TRANSFORMED, TRANSFECTED OR TRANSDUCED HOST CELL. SUCH ANTIBODY HAS REDUCED EFFECTIVE OR ACTIVATION FUNCTIONS OF COMPLEMENT AND / OR ADCC (ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY) AND ARE USEFUL IN THE TREATMENT OF RHEUMATOID ARTHRITIS, PSORIASIS, CANCERS SUCH AS CANCOSTER OF BREAST, PROMOTION OF THE BREAST
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0702888.9A GB0702888D0 (en) | 2007-02-14 | 2007-02-14 | Novel Antibodies |
| US95321007P | 2007-08-01 | 2007-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090107A1 true PE20090107A1 (en) | 2009-03-20 |
Family
ID=42025950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000303A PE20090107A1 (en) | 2007-02-14 | 2008-02-12 | ANTIBODIES BINDING TO THE ANTIGEN IGF-1R |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2010518140A (en) |
| KR (1) | KR20090114449A (en) |
| EA (1) | EA200900991A1 (en) |
| MX (1) | MX2009008754A (en) |
| PE (1) | PE20090107A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3027824A1 (en) * | 2010-02-23 | 2011-09-01 | Sanofi | Anti-alpha2 integrin antibodies and their uses |
| UY33578A (en) | 2010-08-31 | 2012-03-30 | Sanofi Sa | PEPTIDE PEPTIDE OR COMPLEX THAT JOINS INTEGRINE TO (ALPHA) AND METHODS AND USES THAT INVOLVE THE SAME |
| BR112014014418A2 (en) * | 2011-12-15 | 2019-09-24 | Nat Res Council Canada | soluble igf receptor fc fusion proteins and uses thereof |
| CN108473549A (en) * | 2015-10-23 | 2018-08-31 | 阿珀吉科吉尼科斯股份公司 | Single-stranded GITR receptor agonist proteins |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200305995B (en) * | 2001-01-05 | 2004-08-04 | Pfizer | Antibodies to insulin-like growth factor I receptor. |
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US8034904B2 (en) * | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| ES2527871T3 (en) * | 2003-05-01 | 2015-02-02 | Imclone Llc | Fully human antibodies directed against human insulin-like growth factor 1 receptor |
| WO2005058967A2 (en) * | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
| FR2873699B1 (en) * | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF |
| WO2007000328A1 (en) * | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof |
| FR2888850B1 (en) * | 2005-07-22 | 2013-01-11 | Pf Medicament | NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS |
-
2008
- 2008-02-12 JP JP2009549402A patent/JP2010518140A/en active Pending
- 2008-02-12 PE PE2008000303A patent/PE20090107A1/en not_active Application Discontinuation
- 2008-02-12 MX MX2009008754A patent/MX2009008754A/en unknown
- 2008-02-12 EA EA200900991A patent/EA200900991A1/en unknown
- 2008-02-12 KR KR1020097018932A patent/KR20090114449A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009008754A (en) | 2009-11-02 |
| EA200900991A1 (en) | 2010-02-26 |
| JP2010518140A (en) | 2010-05-27 |
| KR20090114449A (en) | 2009-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| PE20121579A1 (en) | BINDING PROTEINS TO THE HUMAN IL-23 ANTIGEN | |
| AR080698A1 (en) | ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND | |
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and their uses | |
| IL259940B2 (en) | A method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists | |
| PE20120622A1 (en) | ANTI-VEGF ANTIBODIES AND THEIR USES | |
| NZ610153A (en) | Novel anti-dr5 antibody | |
| CL2010001544A1 (en) | Humanized monoclonal antibody or binding fragment that binds and neutralizes the human vascular endothelial growth factor (hvegf); composition that includes it; nucleic acid coding; vector; host cell; its use to treat or prevent a disease mediated by vegf; and hybridoma. | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| JP2020500538A5 (en) | ||
| PE20090518A1 (en) | ANTIGEN-BINDING PROTEINS THAT BIND THE INTERLEUKIN-18 (IL-18) RECEPTOR | |
| JP2018534933A5 (en) | ||
| CL2013003140A1 (en) | An isolated human monoclonal antibody or antigen binding fragment thereof that binds to human masp-2; nucleic acid molecule, expression cassette, cell that expresses it, method of production, composition that contains it, article that contains it. | |
| PE20141660A1 (en) | TNF-ALPHA ANTIGEN BINDING PROTEINS WITH INCREASED FcRn BINDING | |
| AR086579A1 (en) | PROTEINS OF UNION TO ANTIGEN | |
| PE20090368A1 (en) | ANTI-IGF ANTIBODIES | |
| RU2008101772A (en) | RECEPTOR ANTAGONISTS FOR TREATMENT OF METASTATIC CANCER | |
| AR061115A1 (en) | ANTI-INTERLEUQUINE ANTIBODIES 18 (IL-18) | |
| PE20170687A1 (en) | BINDING PROTEINS TO CD127 | |
| RU2022111211A (en) | ANTI-CD71 CONJUGATES ACTIVATED ANTIBODY - DRUG AND METHODS OF THEIR APPLICATION | |
| RU2013152164A (en) | ANTI-B7-H3-ANTIBODY | |
| PE20080181A1 (en) | ANTIBODIES THAT BIND TO BETA-AMYLOID PEPTIDE IN THE TREATMENT OF ALZHEIMER | |
| PE20091342A1 (en) | IMMUNOGLOBULINS | |
| MX2009003838A (en) | Anti-cd20 antibodies and methods of use. | |
| AR073770A1 (en) | ISOLATED ANTIBODY THAT LINKS SPECIFICALLY WITH, AND INDUCES THE DEGRADATION OF THE RECEPTOR-3 OF THE HUMAN FIBROBLAST GROWTH FACTOR (FGFR-3), FGFR-3 HUMAN LINK FRAGMENT OF THE SAME, PHARMACEUTICAL COMPOSITION AND PRODUCT COMPOSITION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |